-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, a Phase 1-2 study evaluated the effect of Bentuximab (BV) combined with Nivolumab (Nivo) as the first salvage therapy for patients with relapsed or refractory classic Hodgkin’s lymphoma .
Lymphoma
In the first and second parts, the patient received alternate dosing of BV and Nivo in cycle 1, and then on the same day in cycles 2-4.
stem cell
The results showed that the objective response rate (N=91) was 85%, and 67% of patients achieved complete remission.
immunity
In summary, the long-term follow-up results show that BV and Nivo as the first salvage program have shown long-lasting efficacy and long PFS, especially in patients who directly undergo stem cell transplantation, without additional toxicity problems.
Original source:
ncbi.
ncbi.
nlm.
nih.
gov/?term=Advani+R&cauthor_id=33827139">Advani Ranjana ncbi.
nlm.
nih.
gov/33827139/" target="_blank" rel="noopener">Brentuximab vedotin in Combination with nivolumab relapsed or refractory Hodgkin lymphoma in: 3-year Study Results in this message